NCT07142278RecruitingPhase 1
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
A Phase 1 Study of the Safety and Tolerability of DUVAX, a Dual-Target Alzheimer's Vaccine (Amyloid-Beta and Tau), in Healthy Volunteers
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 19 Aug 2025
- Start date
- 25 Sept 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Nuravax, Inc.
- Diseases
- Alzheimer disease
- NCT number
- NCT07142278
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- From 25 Sept 2026 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent serious illness, surgery, or investigational drug use within 30 days
- Prior amyloid-beta or tau immunotherapy within 1 year
Other illness
- Clinically significant medical or psychiatric illness that may affect safety or study results
- Significant lab abnormalities (e.g., liver, kidney, hematology) or positive HIV/HBV/HCV tests
- History of severe vaccine reactions, autoimmune disease, or significant allergies
Lab values
- Uncontrolled blood pressure, abnormal heart rate, or prolonged QTc interval
Other
- MRI abnormalities (e.g., infarcts, microbleeds, ARIA-E) or contraindications to MRI
- Use of immunosuppressive agents or chronic anticoagulants
Who the study is looking for
- Healthy males and non-pregnant, non-lactating females, 40-65 years old
- BMI between 18.0 and 32.0 kg/m²
- Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI
- Signed informed consent
- Women of childbearing potential: negative pregnancy test and use of effective contraception
- Men: vasectomized or agree to use condoms / not donate sperm during the study period
Age in the registry: 40 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Palm Springs Community Health Center Coordinator of this site? Confirm its status | Miami Lakes | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.